Kymera Therapeutics, Inc. (KYMR)
86.17
-2.83
(-3.18%)
USD |
NASDAQ |
Apr 16, 16:00
86.17
0.00 (0.00%)
After-Hours: 18:44
Kymera Therapeutics Research and Development Expense (Quarterly) : 81.80M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 1.565B |
| Revolution Medicines, Inc. | 292.61M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Structure Therapeutics, Inc. | 68.99M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |